Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its quarterly earnings results on Tuesday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01), FiscalAI reports.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL traded up $0.14 during midday trading on Tuesday, reaching $4.28. 435,620 shares of the stock were exchanged, compared to its average volume of 1,959,367. Zentalis Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $6.95. The business has a 50-day simple moving average of $3.36 and a two-hundred day simple moving average of $2.44. The company has a market capitalization of $304.68 million, a price-to-earnings ratio of -2.25 and a beta of 1.99.

Analysts Set New Price Targets

Several research firms recently issued reports on ZNTL. Guggenheim increased their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.83.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at $37,000. Voleon Capital Management LP acquired a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at $41,000. Algert Global LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $73,000. Corient Private Wealth LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth about $83,000. Finally, State of Wyoming increased its stake in shares of Zentalis Pharmaceuticals by 63.4% during the 2nd quarter. State of Wyoming now owns 73,797 shares of the company’s stock worth $86,000 after purchasing an additional 28,621 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.